CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
REVENUES:
Net product revenues	$ 1,110,381,000	$ 884,522,000	$ 738,416,000
Royalty and other revenues	6,473,000	5,373,000	10,868,000
Total revenues	1,116,854,000	889,895,000	749,284,000
OPERATING EXPENSES:
Cost of sales (excludes amortization of intangible assets)	209,620,000	152,008,000	122,267,000
Research and development	661,905,000	634,806,000	461,543,000
Selling, general and administrative	476,593,000	402,271,000	302,156,000
Intangible asset amortization and contingent consideration	(26,953,000)	(17,690,000)	23,709,000
Impairment of intangible asset	599,118,000	198,700,000	0
Gain on sale of intangible asset	0	(369,498,000)	(67,500,000)
Total operating expenses	1,920,283,000	1,000,597,000	842,175,000
LOSS FROM OPERATIONS	(803,429,000)	(110,702,000)	(92,891,000)
Equity in the loss of BioMarin/Genzyme LLC	(538,000)	(817,000)	(877,000)
Interest income	7,487,000	4,501,000	5,937,000
Interest expense	(39,499,000)	(38,244,000)	(36,642,000)
Other income (expense)	4,929,000	(9,462,000)	(395,000)
LOSS BEFORE INCOME TAXES	(831,050,000)	(154,724,000)	(124,868,000)
Provision for (benefit from) income taxes	(200,840,000)	17,075,000	9,101,000
NET LOSS	$ (630,210,000)	$ (171,799,000)	$ (133,969,000)
NET LOSS PER SHARE, BASIC	$ (3.80)	$ (1.07)	$ (0.92)
NET LOSS PER SHARE, DILUTED	$ (3.81)	$ (1.07)	$ (0.92)
Weighted average common shares outstanding, basic	165,985	160,025	146,349
Weighted average common shares outstanding, diluted	166,219	160,025	146,349